Please assess the completion status of the following clinical trial:

Trial Title: A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Children who have completed a prior phase 3 TransCon hGH trial~2. Children who have not permanently discontinued study drug in the prior trial~3. Written, signed, informed consent of the parent or legal guardian of the subject and written assent of the subject as required by the IRB/HREC/IEC~Exclusion Criteria:~1. Poorly-controlled diabetes mellitus (HbA1c ≥ 8.0%) or diabetic complications~2. Evidence of closed epiphyses, defined as bone age \> 14.0 years for females or \> 16.0 years for males~3. Major medical conditions unless approved by Medical Expert~4. Known hypersensitivity to the components of the trial medication~5. Likely to be non-compliant with respect to trial conduct (in regards to the subject and/or the parent/legal guardian/caregiver)~6. Pregnancy~7. Any other reason that in the opinion of the investigator would prevent the subject from completing participation or following the trial schedule

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- TransCon hGH (Type: EXPERIMENTAL): Once weekly subcutaneous injection of TransCon hGH

Based on this trial design, predict the completion outcome and termination type (if applicable).